$LGND News

Here's How Much $1000 Invested In Ligand Pharmaceuticals 20 Years Ago Would Be Worth Today

Ligand to Host Investor Day on December 8, 2026

Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026

Here's How Much $1000 Invested In Ligand Pharmaceuticals 15 Years Ago Would Be Worth Today

Full Transcript: Ligand Pharmaceuticals Q2 2026 Earnings Call

Is Ligand Pharmaceuticals (LGND) Below Fair Value As It Funds AvenCell?

Ligand Pharmaceuticals (LGND) Stock May Be 27% Undervalued After A New Royalty Deal

Is Ligand Pharmaceuticals (LGND) Using AvenCell CAR-T Royalties To Redefine Its Cash-Flow Playbook?

Ligand Pharmaceuticals (NASDAQ:LGND) Flashes Strong Trend and High-Growth Momentum Despite Setup Caution

Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones

Barclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345

HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $358 Price Target

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $397

Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®

Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners

Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million

Sydnexis Signs $23M Agreement With Ligand Pharmaceuticals To Sell Its Royalty Rights Associated With Net Sales Of Ryjunea In EMEA

Here’s How Much You Would Have Made Owning Ligand Pharmaceuticals Stock In The Last 5 Years

Ligand Pharmaceuticals: The Multiple Is The Whole Bet; Hold